Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Oct 28;12(11):e1072. doi: 10.1002/ctm2.1072

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.

This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Landscape of cell clusters in tumour and MPE samples of osteosarcoma patients delineated by scRNA‐seq analysis. (A) Workflow of our study design. Eight tumour tissues and seven MPE samples from individual patients were performed for the scRNA‐seq analysis, and two other MPE samples were collected for cellular cytotoxic and flow cytometry tests in the current study. (B) The UMAP plots demonstrate the 13 mainly identified cell clusters in all OS patients or from different sample types. (C) Dotplot exhibits the expression levels of canonical markers in each cell cluster. Cell number (D) and (E) proportion of assigned cell clusters in different sample types were demonstrated. (F) The bar plot presented the relative proportion of OC and T/NK cells among immune cells (CD45⁺) between primary tumour and MPE samples. A comparison of the cellular proportion between the groups was performed using the Wilcoxon test.